Sustained-Release Injectable Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sustained-Release Injectable Drug Delivery
A review on the current status of long-acting injectables, including commercially marketed products. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s6-s13

This article is part of a special issue on Drug Delivery


(GEORGE DIEBOLD, PHOTODISC, GETTY IMAGES)
Reproducible sustained delivery of a drug at a target site is one of the main themes in controlled drug-delivery systems. The most commonly used drug-delivery systems, which can release drugs longer than one week, are parenteral injections and implants. Certain implant systems can deliver drugs for more than one year, and the longest drug delivery can be achieved by biodegradable or nonbiodegradable implant systems. Some examples of US Food and Drug Administration approved long-acting products are listed in Table I.


Table I: Examples of US Food and Drug Admistration-approved long-acting formulations on the market.*
Long-acting injectable formulations offer many advantages when compared with conventional formulations of the same compounds. These advantages include the following: a predictable drug-release profile during a defined period of time following each injection; better patient compliance; ease of application; improved systemic availability by avoidance of first-pass metabolism; reduced dosing frequency (i.e., fewer injections) without compromising the effectiveness of the treatment; decreased incidence of side effects; and overall cost reduction of medical care.

This review focuses on the current status and explores long-acting injectables with special attention to marketed products. Injectable routes, types of long-acting injectables (i.e., oil-based injections, injectable drug suspensions, injectable microspheres, and injectable in situ systems), drugs and polymers for depot injections, commercially available depot injections, and future injectable sustained-release drug-delivery systems are also discussed.

Types of injectable routes of administration

It is well recognized that the advantages of parenteral injections are immediate systemic drug availability and rapid onset of action. Another significant and unique advantage of parenteral injection is a long-term drug delivery by the formation of a depot or reservoir at the injection site after drug administration. As depicted in Table I, intravenous (IV) injection can be used for certain prolonged acting drugs due to the drugs' long half-lives in the body after IV administration. The sustained release of drug from these preparations is a result of the long-acting property of drug and its residence in the bloodstream or the bone.

In general, there are two routes by which long-acting parenteral injections are most frequently administered: intramuscular (IM) and subcutaneous (SC). To determine the injectable route of administration for long-term delivery formulations, many factors should be considered such as safety profile, ease of administration, patient's limited mobility, area for target injection sites, quality of life and cost of therapy (1). In many cases, SC is the preferred route for administering a drug by injection because of greater area for target injection sites, use of shorter needles, ease of self-administration, less discomfort and inconvenience for patients, and better safety profile (1). Various insulin products are given SC, and this route of administration presumably continues to represent the primary route of delivery for protein-based drugs. However, the volumes of SC injection are usually limited to no more than 1–2 mL, and only nonirritant substances can be injected by a SC route because irritants can cause pain, necrosis, and sloughing at the site of injection. On the other hand, greater injection volumes (2–5 mL) can be given by the IM route. Mild irritants, oils, and suspensions can be injected by IM route in the large skeletal muscles (i.e., deltoid, triceps, gluteus maximus, and rectus femoris) because these muscles are less richly supplied with sensory nerves and are more vascular. Therefore, a few SC injections for long-term release can be found on the market (i.e., Depo-SubQ Provera 104, Pfizer (New York); Nutropin Depot, Genentech (South San Francisco, CA), and Eligard, sanofi-aventis (Paris), and many long-acting IM injections are available on the market (oil-based injections, injectable drug suspensions, and injectable microspheres).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here